MS
PTGX icon

Maven Securities’s Protagonist Therapeutics PTGX Stock Holding History

Maven Securities’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,700
Closed -$466K – 1071
2022
Q1 		$466K Buy
+19,700
New +$555K 0.02% 562
2021
Q1 		– Sell
-90,000
Closed -$1.81M – 1267
2020
Q4 		$1.81M Buy
+90,000
New +$1.94M 0.18% 149

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Maven Securities's PTGX Position: Q2 2022 in Review

Maven Securities sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 19,700 shares — an estimated $466K sold.

Maven Securities first reported a position in PTGX in Q4 2020 and held it in 2 quarters. The position peaked at $1.81M in Q4 2020. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

  • Maven Securities reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Maven Securities sold 19,700 Protagonist Therapeutics shares in Q2 2022, an estimated $466K.
  • Maven Securities first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Protagonist Therapeutics position peaked at $1.81M in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Maven Securities's 13F filing for Q2 2022, filed 15 Aug 2022.